Michael Cleman, MD
Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2023
Impact of sex on Transcatheter aortic valve replacement outcomes: Results of a single-center study
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Francese D, Kaple R, Cleman M, Lansky A, Forrest J. Impact of sex on Transcatheter aortic valve replacement outcomes: Results of a single-center study. International Journal Of Cardiology 2023, 398: 131643. PMID: 38065329, DOI: 10.1016/j.ijcard.2023.131643.Peer-Reviewed Original ResearchNew-generation valvesTranscatheter Aortic Valve Replacement OutcomesImpact of sexTAVR outcomesArtery diseaseYale-New Haven HospitalSTS mortality scorePeripheral artery diseaseSingle-center studyCoronary artery diseaseKaplan-Meier curvesLog-rank testNew Haven HospitalSex-based disparitiesSignificant differencesCardiovascular comorbiditiesSAPIEN 3Transfemoral accessSAPIEN XTConsecutive patientsCox modelingMortality scoreEvolut RFemale sexEvolut PROImpact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECGColchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz C, Parise H, Lansky A. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 2023, 13: e067910. PMID: 36828654, PMCID: PMC9971831, DOI: 10.1136/bmjopen-2022-067910.Peer-Reviewed Original ResearchConceptsStandard of careHigh-intensity rosuvastatinElectronic medical recordsCOVID-19 diseaseMedical recordsPrimary endpointThromboembolic eventsYale New Haven Health SystemSevere COVID-19 diseaseCOVID-19Prespecified primary endpointVenous thromboembolic eventsRisk of progressionCombination of colchicineSafety monitoring boardCare armHispanics/LatinosTherapeutic anticoagulationIndex hospitalisationIll patientsMedian ageFuture trialsEffect of colchicineClinical trialsMonitoring board
2022
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
Patel K, Lansky A, Kereiakes D, Windecker S, Cristea E, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Brogno D, Janssens L, Vrolix M, Gómez-Blázquez I, Sahul Z, Kabour A, Salido L, Cleman M, Saito S, Leon M, Baumbach A, Investigators I. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100004. PMID: 39130138, PMCID: PMC11308031, DOI: 10.1016/j.jscai.2021.100004.Peer-Reviewed Original ResearchDrug-eluting stentsTarget lesion failureDP-EESComplex lesionsLesion failureAdverse eventsLesion complexityMajor adverse cardiac eventsSingle-blind clinical trialEnd pointAdverse cardiac eventsChronic coronary syndromePrimary end pointSecondary end pointsTarget lesion revascularizationTarget vessel failureComplex coronary lesionsPercutaneous coronary interventionEverolimus-eluting stentsDrug eluting stentsHigh rateLesion revascularizationCoronary syndromeCardiac eventsCoronary intervention
2021
Impact of Persistent vs. Transient Conduction Abnormalities Within 7 Days Post-TAVR on Mortality: Results of a Single-Center Prospective Registry
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Kaple R, Cleman M, Lansky A, Forrest J. Impact of Persistent vs. Transient Conduction Abnormalities Within 7 Days Post-TAVR on Mortality: Results of a Single-Center Prospective Registry. Cardiovascular Revascularization Medicine 2021, 28: s43. DOI: 10.1016/j.carrev.2021.06.099.Peer-Reviewed Original ResearchIMPACT OF SEX ON OUTCOMES IN TAVR: RESULTS FROM A SINGLE CENTER PROSPECTIVE REGISTRY
Wang Y, Yang Y, See C, tirziu D, Papoutsidakis N, Kaple R, Cleman M, Lansky A, Forrest J. IMPACT OF SEX ON OUTCOMES IN TAVR: RESULTS FROM A SINGLE CENTER PROSPECTIVE REGISTRY. Journal Of The American College Of Cardiology 2021, 77: 900. DOI: 10.1016/s0735-1097(21)02259-2.Peer-Reviewed Original ResearchIMPACT OF PACEMAKER IMPLANT ≤ 30 DAYS POST TAVR ON MORTALITY: RESULTS OF A SINGLE CENTER PROSPECTIVE REGISTRY
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Kaple R, Cleman M, Lansky A, Forrest J. IMPACT OF PACEMAKER IMPLANT ≤ 30 DAYS POST TAVR ON MORTALITY: RESULTS OF A SINGLE CENTER PROSPECTIVE REGISTRY. Journal Of The American College Of Cardiology 2021, 77: 974. DOI: 10.1016/s0735-1097(21)02333-0.Peer-Reviewed Original ResearchAN ENDOSCOPICALLY GUIDED TRANSESOPHAGEAL ECHOCARDIOGRAM-A NOVEL APPROACH TO TRANSCATHETER MITRAL VALVE REPAIR IN THE SETTING OF A ZENKER'S DIVERTICULUM
Tangel R, Agarwal V, Forrest J, Cleman M, Kaple R, Singh P, Mehta H, Hughes M, Tarangelo N, Muniraj T, DaSilva P, Balan S. AN ENDOSCOPICALLY GUIDED TRANSESOPHAGEAL ECHOCARDIOGRAM-A NOVEL APPROACH TO TRANSCATHETER MITRAL VALVE REPAIR IN THE SETTING OF A ZENKER'S DIVERTICULUM. Journal Of The American College Of Cardiology 2021, 77: 2457. DOI: 10.1016/s0735-1097(21)03812-2.Peer-Reviewed Original Research
2019
TCT-763 Valve in Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement: Real World Outcomes From the National Inpatient Sample (2013–2016)
Kim G, Geirsson A, Cleman M, Forrest J, Kaple R. TCT-763 Valve in Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement: Real World Outcomes From the National Inpatient Sample (2013–2016). Journal Of The American College Of Cardiology 2019, 74: b748. DOI: 10.1016/j.jacc.2019.08.902.Peer-Reviewed Original Research
2018
USE OF INTRAVASCULAR ULTRASOUND TO GUIDE INTERVENTION IN ACUTE MYOCARDIAL INFARCTION
Sciria C, Spatz E, Jhamnani S, Cleman M. USE OF INTRAVASCULAR ULTRASOUND TO GUIDE INTERVENTION IN ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2018, 71: a2137. DOI: 10.1016/s0735-1097(18)32678-0.Peer-Reviewed Original Research
Clinical Care
Overview
Michael Cleman, MD, is an interventional cardiologist and focuses on adult structural heart disease (defects or disorders in the heart’s valves).
Dr. Cleman says he became interested in medicine after participating in independent research studies in high school and college. One program in college with a cardiologist convinced him that cardiology was the right career for him.
“It was an exciting time. Everything was moving very quickly and there was so much enthusiasm around the coronary field,” Dr. Cleman says.
He came to Yale in the early 1980s to do research in electrophysiology but ended up in the catheterization lab and performing angioplasty procedures. He became involved in the original studies and applications of what were then novel technologies—coronary stents (devices that keep the coronary arteries open to treat heart disease), rotational atherectomy(a procedure that removes plaque that clogs coronary arteries), and intravascular ultrasound.
“We were one of the first three or four people in the United States to do coronary stents, and one of the first to do rotational atherectomy,” he says.
Today, Dr. Cleman’s clinical work includes stents and diagnostic procedures, as well as TAVR (transcatheter aortic valve replacement), and mitral valve clip placements.
The best part of his job, Dr. Cleman says, is the variety—and helping to train the next generation of physicians. He also enjoys working with patients and describes himself as laid-back and approachable.
“I have a lot of experience, and I have watched how things have progressed. It’s reassuring to tell patients where things were and where they are now,” he says. “The changes have been dramatic and there are so many different treatments we can offer.”
Dr. Cleman’s clinical research interests include structural heart disease.
Clinical Specialties
Fact Sheets
Coronary Atherosclerosis Treatments
Learn More on Yale MedicineStructural Heart Disease
Learn More on Yale MedicineHeart Disease in Women
Learn More on Yale MedicineCoronary Artery Disease (CAD)
Learn More on Yale Medicine
Board Certifications
Cardiovascular Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1985
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1980
Yale Medicine News
News
News
Get In Touch
Contacts
Cardiovascular Medicine
PO Box 208056, 333 Cedar Street
New Haven, CT 06520-8056
United States
Locations
Fitkin Memorial Pavilion
Academic Office
789 Howard Avenue, Ste 3rd Floor
New Haven, CT 06519
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.